Amesite Inc.

Amesite Inc. has entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. This agreement allows the company to offer and sell shares of its common stock, up to a specified "Maximum Amount," through the agent from time to time. Any net proceeds generated from these sales are intended for general corporate and working capital purposes. The agent will receive a 3.0% commission on the gross proceeds from each sale.

Amesite Inc. held its Annual Meeting on July 13, 2026, where stockholders approved several key proposals. These included an amendment to the 2018 Equity Incentive Plan to increase available shares by 1,000,000 for general issuance and another 1,000,000 for incentive stock options. Stockholders also approved the issuance of 1,393,732 shares each for Series A-1 and Series A-2 warrants. Additionally, two Class II directors were elected, and the appointment of Novogradac & Company LLP as the independent auditor was ratified.

Amesite Inc. has filed its Definitive Proxy Statement (DEF 14A) announcing its Annual Meeting of Stockholders to be held virtually on July 13, 2026. Key agenda items include the election of two Class II Directors, ratification of Novogradac & Company LLP as the independent auditor, an amendment to the 2018 Equity Incentive Plan to increase share availability, and approval for the issuance of shares upon the exercise of Series A-1 and Series A-2 warrants. The company is utilizing the 'Notice and Access' method for distributing proxy materials.

Amesite Inc. filed an S-1/A detailing estimated expenses for its securities offering, totaling $60,674.56, which includes SEC registration, accounting, legal, and miscellaneous fees. The company also disclosed recent sales of unregistered securities, including 121,250 options to employees in 2025 and 14,083 shares to consultants in 2023. Additionally, the filing outlined the company's indemnification policies for directors and officers, consistent with Delaware law.

Amesite Inc. announced it secured its largest enterprise customer to date for its AI-native NurseMagic documentation platform, covering approximately 2,700 patients. This deployment validates the company's enterprise strategy and AI-first infrastructure, demonstrating scalable and cost-efficient execution in non-acute care. The platform is expected to reduce administrative burden by up to 16 hours per caregiver per week. The company also highlighted an 18% reduction in operating spend over the last six quarters while supporting a growing customer base.

Amesite Inc. announced it has secured its largest enterprise customer to date, representing an approximately 2,700-patient census for its NurseMagic AI documentation platform. This deployment validates the company's enterprise strategy and is expected to significantly reduce administrative burden for caregivers. Amesite also highlighted its financial discipline, with an 18% reduction in operating spend over the last six quarters, and a strong sales pipeline with thousands of daily web visits and advanced discussions for further expansion.

Amesite Inc. completed a registered direct offering and private placement on April 28, 2026, raising approximately $2.6 million in gross proceeds, which is intended for working capital and general corporate purposes. This financing is critical given management's expressed substantial doubt about the company's ability to continue as a going concern. For the nine months ended March 31, 2026, the company reported a significant increase in net revenue to $285,678, up from $54,700 in the prior year, and an improved net loss of $(2,052,875) compared to $(2,693,100).

Amesite Inc. filed an S-1 registration statement for the resale of up to 4,836,245 shares of common stock by selling stockholders. This includes shares issued directly and those issuable upon the exercise of various warrants, which could generate approximately $5.38 million in gross proceeds for the company if exercised for cash. The company, which has pivoted to AI-powered healthcare solutions, reported significant net losses in recent fiscal years and expressed substantial doubt about its ability to continue as a going concern.

Amesite Inc. announced the closing of its previously announced registered direct offering and concurrent private placement, generating approximately $2.6 million in gross proceeds. The offerings included the sale of 696,866 shares of common stock at $1.435 per share, along with unregistered Series A-1 and A-2 warrants to purchase an equal number of shares. Additionally, an insider-led private placement closed, involving 418,118 shares and warrants at the same price. The company intends to use the net proceeds for general corporate purposes, including working capital, and believes its stockholders' equity now exceeds Nasdaq's minimum requirement.

Amesite Inc. announced concurrent registered direct and private placement offerings, expecting approximately $2 million in gross proceeds upfront, with an additional $4 million potential from warrant exercises. Concurrently, the company also secured an insider-led private placement for approximately $600,000. These offerings, totaling $2.6 million upfront and up to $6 million potentially, are intended for general corporate purposes and to help the company regain compliance with Nasdaq's minimum stockholder's equity requirement of $2.5 million.